117942-41-3

Upstream product

• 3970-21-6 2-Methoxyethoxymethyl chloride 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 117942-42-4 diethyl 4-<(2-methoxyethoxy)methoxy>benzalmalonate 
• 104575-17-9 4-(2-Methoxyethoxymethoxy)benzonitrile 
• 113102-02-6 4-(2-methoxyethoxy)methoxybenzyl alcohol 
• 592466-63-2 1-ethynyl-4-(2-methoxy-ethoxymethoxy)-benzene 
• 1447665-45-3 2,2,2-trifluoro-1-(4-((2-methoxyethoxy)methoxy)phenyl)-ethanol 
• 1435932-86-7 3-(4-((2-methoxyethoxy)methoxy)phenyl)-2-oxopropanoic acid 
• 1431505-88-2 methyl 2-hydroxy-3-(4-methoxyethoxymethoxyphenyl)acrylate 
• 1431506-07-8 (R)-2-hydroxy-3-(4-methoxyethoxymethoxyphenyl)propanoic acid 
• 1431506-01-2 (R)-1-methyl 3-(4-(2-methoxyethoxy)methoxyphenyl)-2-pivaloyloxypropanoate 
• 1431505-94-0 (Z)-methyl 3-(4-(2-methoxyethoxy)methoxyphenyl)-2-pivaloyloxyacrylate 
• 1431505-82-6 (E/Z)-methyl 2-(dimethylamino)-3-(4-(2-methoxyethoxy)methoxyphenyl)acrylate 
• 113102-01-5 p-methoxyethoxymethoxy benzoic acid 
• 1345676-76-7 C₂₅H₄₁N₇O₆ 
• 1345676-75-6 C₂₃H₃₄N₆O₄ 

Relevant academic research and scientific papers

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE

The invention relates to a compound of Formula (I): (A')x-(A)-(B)-(Z)-(L)-(D), wherein: (A) is heteroaryl or aryl; each (A'), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl,

LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (Α'), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyan

Synthesis of tokaramide A, a cysteine protease inhibitor from marine sponge Theonella aff. mirabilis

The first synthesis of tokaramide A (1) is described. Tokaramide A (1) was synthesized via the peptide with a side-chain unprotected arginine residue on Weinreb AM resin by reductive cleavage.

Stereoselective synthesis of β-methoxytyrosine derivatives for identification of the absolute configuration of callipeltin E

Asymmetric syntheses of all diastereoisomers of β-methoxytyrosine, an unusual amino acid contained in callipeltin A, were accomplished starting from a cinnamyl ester derivative. The stereochemistry of β-methoxytyrosine in callipeltin E was estimated to be

Synthesis of biphenyltrienes as probes for β-amyloid plaques

We report a series of p-hydroxy-, p-amino-, p-monomethylamino-, and p-monofluoroethylamino-substituted biphenyltrienes that displayed high binding affinities to β-amyloid plaques. In an in vitro binding assay using postmortem brain homogenates of Alzheime

BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR

The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (-NHCOCH3 group), a cyano group (-CN group), a formyl group (-CHO group), -COOR1 (R1 is hydrogen or C1-C4 alkyl) , -O(CH2)nCOOR2 (n=1-7: R2 is hydrogen or C1-C4 alkyl) , -OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., -OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., -OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides

The invention concerns novel azole or triazole derivatives of formula (I), wherein X, Ar1, Ar2, Ar3, A, B, and R1 are as defined herein, their preparation method and their use as fungicides.

Non-imidazole heterocyclic histamine H3 receptor antagonists

Continued exploration of the SAR around the lead imidazopyridine histamine H3 antagonist 1 has led to the discovery of several related series of heterocyclic histamine H3 antagonists. The synthesis and SAR of indolizine, indole and p